Top Page
Atrys Health SA
(BME:ATRY)
Atrys Health SA (ATRY) vs. iShares MSCI Spain ETF (EWP)
Atrys Health SA Business Overview & Revenue Model
Atrys Health SA Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 212.74M | 201.57M | 186.99M | 121.01M | 31.40M | Gross Profit |
| 145.38M | 141.77M | 154.51M | 100.89M | 24.25M | EBIT |
| -10.55M | -1.58M | 8.37M | -12.34M | 983.03K | EBITDA |
| 19.07M | 31.91M | 16.63M | 5.87M | 4.81M | Net Income Common Stockholders |
| -31.77M | -45.59M | -23.47M | -23.20M | ― |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 29.29M | 42.18M | 35.84M | 40.57M | 17.60M | Total Assets |
| 584.19M | 629.00M | 705.28M | 565.63M | 175.78M | Total Debt |
| 166.13M | 254.00M | 258.74M | 204.51M | 71.46M | Net Debt |
| 145.76M | 212.17M | 224.44M | 169.39M | 53.98M | Total Liabilities |
| 330.95M | 339.12M | 367.71M | 291.65M | 100.45M | Stockholders Equity |
| 253.10M | 289.87M | 337.63M | 274.03M | 75.33M |
| Cash Flow | Free Cash Flow | |||
| -10.14M | -14.24M | -30.59M | -3.87M | ― | Operating Cash Flow |
| 3.00M | -1.09M | -15.43M | 4.69M | ― | Investing Cash Flow |
| -12.95M | 395.00K | -80.59M | -2.45M | ― | Financing Cash Flow |
| -11.51M | 8.19M | 94.77M | 14.08M | 62.63M |
Atrys Health SA Technical Analysis
Atrys Health SA Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.37B | 3.26 | -45.10% | 3.30% | 16.81% | 0.02% | |
44 Neutral | €208.18M | ― | -11.64% | ― | 5.54% | 30.33% | |
| €2.35B | 229.17 | 0.69% | 1.35% | ― | ― | ||
| €6.28B | 35.53 | 3.37% | ― | ― | ― | ||
| €2.83B | 20.56 | 25.24% | 1.59% | ― | ― | ||
| $1.72B | 78.07 | 10.15% | 0.72% | ― | ― | ||
| €629.62M | 18.51 | 22.52% | 2.80% | ― | ― |
Atrys Health SA Corporate Events
Atrys Health SA has announced a succession plan involving the appointment of Marian Isach as the future CEO, succeeding Isabel Lozano, who will remain as a non-executive director. Santiago de Torres will transition to a non-executive chairman role. This plan reflects Atrys’ commitment to internal talent and governance best practices. The company also reported an 11.2% increase in revenue for the first quarter of 2025, driven by growth across all business areas, particularly in Oncology and Diagnosis.
Atrys Health SA released its first quarter 2025 results, highlighting its strategic focus on expanding its customer base and business lines. The announcement underscores the company’s commitment to growth and market share enhancement, although it acknowledges potential risks and uncertainties that could impact future performance.
Atrys Health S.A. has announced the convening of its Ordinary General Shareholders’ Meeting to be held on June 12, 2025, with a second call on June 13, 2025, in Madrid. The agenda includes the approval of annual accounts, re-election of KPMG as auditors, appointment and re-election of directors, and modifications to the remuneration policy for directors. These decisions are crucial for the company’s governance and financial oversight, impacting stakeholders by ensuring transparency and continuity in leadership.
Atrys Health SA has announced a leadership succession plan, with Marian Isach set to become the new CEO, replacing Isabel Lozano, who will transition to a non-executive director role. Santiago de Torres will shift from executive to non-executive chairman. This move is part of a broader generational change strategy initiated in 2024, aimed at promoting internal talent and ensuring continuity in the company’s leadership model. The company also reported an 11.2% revenue increase in the first quarter of 2025, driven by growth across all business areas, particularly in Oncology and Diagnosis, highlighting Atrys’ ongoing expansion and market strength.
Atrys Health, S.A. has announced a webcast for analysts and investors to present its first quarter 2025 results, scheduled for May 7, 2025. This event, featuring CEO Isabel Lozano and CFO José María Huch, is part of Atrys’ ongoing efforts to maintain transparency with stakeholders and could impact investor confidence and market positioning.
Atrys Health, S.A. has outlined its remuneration policy for directors for 2022-2024, which includes fixed and variable components linked to performance objectives. The policy, approved by a significant majority of shareholders, reflects the company’s strategic focus on aligning executive compensation with its operational and sustainability goals.
Atrys Health SA reported significant growth in 2024, conducting over 9 million medical acts, marking an 18.5% increase from the previous year. The company’s expansion in health monitoring, tele-diagnoses, and oncology services underscores its strengthened market position and commitment to personalized healthcare solutions.
Atrys Health SA reported a revenue increase of 5.5% in 2024, reaching 212.7 million euros, with a significant EBITDA growth of 13.8% to 48.5 million euros. The company reduced its negative consolidated result by 31% and improved its leverage ratio, reflecting the strength and efficiency of its business model. Atrys experienced growth across all business areas, particularly in oncology, driven by its activities in Mexico, and saw notable revenue increases in Spain, Portugal, and Latin America.
Atrys Health, S.A. announced that its subsidiary, Bienzobas Salud, continues to enhance its oncological advisory services by adhering to the European Society for Medical Oncology’s standards for sustainable cancer care. This approach ensures that patients receive appropriate treatments based on clinical benefits while maintaining cost-effectiveness, supporting both public and private healthcare systems in Spain.